<DOC>
	<DOCNO>NCT02560376</DOCNO>
	<brief_summary>This open-label positron emission tomography/computed tomography ( PET/CT ) study investigate diagnostic performance evaluation efficacy 68Ga-NOTA-exendin-4 insulinoma nesidioblastosis patient . A single dose 55.5-111 Mega-Becquerel ( MBq ) 68Ga-NOTA-exendin-4 injected intravenously . Visual semiquantitative method use assess PET/CT image .</brief_summary>
	<brief_title>68Ga-NOTA-exendin-4 PET/CT Localization Insulinoma Diagnosis Nesidioblastosis</brief_title>
	<detailed_description>68Ga-NOTA-exendin-4 optimal probe target GLP-1R . The investigator determine use 68Ga-NOTA-exendin-4 PET/CT detection insulinomas , compare diagnostic value conventional imaging . GLP-1R imaging , specifically express pancreatic beta cell surface , might help diagnosis different type nesidioblastosis ( ie . focal diffuse type ) , may improve treatment strategy nesidioblastosis . The investigator determine use 68Ga-NOTA-exendin-4 PET/CT differentiate nesidioblastosis .</detailed_description>
	<mesh_term>Insulinoma</mesh_term>
	<mesh_term>Nesidioblastosis</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Patients hypoglycaemia presence neuroglycopenic symptom document Whipple 's triad . Biochemically proven endogenous hyperinsulinemic hypoglycaemia ( plasma glucose concentration &lt; 3.0 mM , insulin &gt; 3 ÂµU/ml , Cpeptide &gt; 0.6 ng/ml ) . Conventional imaging within 1 month Signed write consent Age 6 year ( congenital hyperinsulinemic symptom onset school age also subject study ) Pregnancy Breastfeeding Renal function : serum creatinine &gt; 3.0 mg/dl Known allergy exendin4 Any medical condition , opinion investigator , may significantly interfere study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>PET/CT</keyword>
	<keyword>glucagon-like peptide-1 receptor ( GLP-1R ) imaging</keyword>
</DOC>